Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VEEBOSE-GM is a fixed-dose combination oral anti-diabetic medication marketed by Biomax Biotechnics. It contains three active ingredients: acarbose and voglibose, which are alpha-glucosidase inhibitors, and metformin, a biguanide. Acarbose and voglibose work by inhibiting the alpha-glucosidase enzymes in the small intestine, thereby delaying the digestion and absorption of carbohydrates and reducing postprandial blood glucose levels. Metformin acts primarily by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. This combination is used for the management of type 2 diabetes mellitus, particularly when glycemic control is not achieved with monotherapy or dual therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VEEBOSE-GM.